PMGC (NASDAQ:ELAB – Get Free Report) announced its earnings results on Friday. The company reported ($0.61) EPS for the quarter, FiscalAI reports. The company had revenue of $1.31 million for the quarter.
PMGC Price Performance
Shares of NASDAQ ELAB traded up $0.02 during mid-day trading on Friday, hitting $0.91. 575,009 shares of the stock traded hands, compared to its average volume of 4,224,617. The firm has a 50 day simple moving average of $1.15 and a two-hundred day simple moving average of $4.06. PMGC has a twelve month low of $0.84 and a twelve month high of $309.12. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.45 and a quick ratio of 1.43. The company has a market cap of $1.06 million, a PE ratio of -0.01 and a beta of -0.25.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PMGC in a research note on Friday, June 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
About PMGC
Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021. Elevai Labs, Inc was incorporated in 2020 and is based in Newport Beach, California.
See Also
- Five stocks we like better than PMGC
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for PMGC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMGC and related companies with MarketBeat.com's FREE daily email newsletter.
